drugset / Trial / NCT03678129

GABA Pathways in Autism Spectrum Disorder (ASD)

NCT03678129

Completed 109 enrolled King's College London
Non-randomizedParallel-groupDouble-blindBasic science

Summary

This study investigates the brain response to a single acute dose of a GABAa receptor acting drug (Benzodiazepine or positive allosteric modulator) compared to a single dose of placebo in adults with and without autism spectrum disorder.

Timeline

Start
2018-12-07
Primary completion
2025-06-27
Completion
2025-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD7325 Small molecule 10 mg Oral
Subject AZD7325 Small molecule 20 mg Oral
Subject Clobazam Small molecule 5 mg